Profiling mammalian cell differentiation by MALDI-TOF MS: Developing a highly reproducible and robust sample preparation workflow

Applications | 2020 | BrukerInstrumentation
MALDI, LC/TOF, LC/MS, LC/MS/MS
Industries
Clinical Research
Manufacturer
Bruker

Significance of the Topic


Profiling mammalian cell differentiation is critical in drug discovery and regenerative medicine because it provides a rapid, label-free insight into cellular phenotypes. Traditional fluorescence-based assays are often time-consuming, costly, and require extensive sample manipulation. The MALDI-TOF MS approach described here leverages recent advances in instrumentation to deliver high-throughput, cost-effective, and robust phenotyping of stem cell states, enabling faster decision-making in research and industry.

Objectives and Study Overview


The main goal of this work was to develop and validate a universal sample preparation workflow for whole-cell MALDI-TOF MS analysis of mammalian cells. Specifically, the study aimed to:
  • Optimize initial sample handling, including cell washing, freezing, and fixation methods.
  • Compare common MALDI matrices (SA, CHCA, DHB) for sensitivity and reproducibility.
  • Establish optimal cell number ranges for analysis.
  • Demonstrate the ability to distinguish naïve versus differentiating stem cell populations using multivariate analysis.

Methodology and Instrumentation


The experimental workflow was systematically evaluated using four human cell lines (HEK293, U2OS, MCF7, THP-1) and mouse embryonic stem cells (mESCs). Key steps included:
  • Sample handling: Cells were pelleted by centrifugation, then subjected to either direct analysis, snap-freezing before or after PBS washes, or fixation in paraformaldehyde or methanol.
  • Matrix preparation: Sinapinic acid (SA), α-cyano-4-hydroxycinnamic acid (CHCA), and 2,5-dihydroxybenzoic acid (DHB) were tested at various concentrations in 1:1 acetonitrile:water with 0.1% TFA.
  • Deposition: Manual spotting of 1 µL or automated dispensing of 200 nL on Bruker AnchorChip targets using a Mosquito robot.
  • MS analysis: rapifleX PharmaPulse MALDI-TOF instrument (2000–20 000 Da range, linear positive mode, 10 kHz laser frequency, optimized laser power, 10 000 shots in random walk pattern).
  • Data processing: FlexAnalysis 4.0 and Perseus software with custom statistical scripts for peak detection and multivariate analysis.

Main Results and Discussion


Key findings from the optimisation experiments were:
  • Freeze-thaw cycles of cell pellets significantly increased membrane permeability, yielding 50–80% more detected spectral features compared to intact cells. The order of freezing and washing had minimal impact.
  • An optimal cell deposition range of 50–2000 cells/spot was identified; higher cell numbers impaired ionization and spectral quality.
  • Matrix comparison revealed CHCA as the superior choice. It produced the most consistent spectra across replicates, >98% peak identification for the top five signals, and up to a ten-fold higher signal-to-noise ratio compared with SA and DHB.
  • Applying the optimized workflow to mESCs enabled clear separation of naïve and differentiating populations via PCA and hierarchical clustering. Distinct m/z features were identified that underlie phenotypic differences.

Benefits and Practical Applications of the Method


This MALDI-TOF MS workflow offers several practical advantages:
  • Label-free profiling reduces reagent costs and avoids interference from fluorescent tags.
  • Rapid turnaround (<1 hour from culture to data) accelerates experimental workflows.
  • Low sample consumption and minimal cleanup streamline handling.
  • High reproducibility and sensitivity support reliable phenotyping.
  • Compatibility with automated liquid handling and target spotting facilitates scale-up to high-throughput screening.

Future Trends and Potential Applications


Several emerging directions can expand the utility of this approach:
  • Full automation of sample preparation and data acquisition for large-scale drug screening.
  • Integration with machine-learning algorithms for automated phenotype classification.
  • Extension to additional cell types and complex co-culture systems.
  • Combining MALDI-TOF profiling with orthogonal omics data (proteomics, metabolomics) for multi-layered phenotypic insights.
  • Development of targeted mass spectral libraries for rapid identification of differentiation markers.

Conclusion


The presented sample preparation workflow for whole-cell MALDI-TOF MS demonstrates a robust, sensitive, and reproducible method for distinguishing stem cell states. By optimizing freeze-thaw handling, cell density, and matrix selection—particularly using CHCA—this approach enables rapid, label-free phenotyping. Its compatibility with automation and high-throughput formats makes it a promising platform for drug discovery and broader cellular screening applications.

Reference


  • [1] Ritorto MS et al. Nature Communications 5, 4763 (2014).
  • [2] De Cesare V et al. Cell Chemical Biology 25(9), 1117–1127.e4 (2018).
  • [3] Winter M et al. SLAS DISCOVERY 23(6), 561–573 (2018).
  • [4] Heap RE et al. SLAS DISCOVERY 22(10), 1193–1202 (2017).
  • [5] Guitot K et al. Anal. Bioanal. Chem. 409(15), 3767–3777 (2017).
  • [6] Weigt D et al. Cell Chemical Biology (2019).
  • [7] Winter M et al. SLAS DISCOVERY (2019).
  • [8] Tyanova S et al. Nature Methods 13, 731 (2016).
  • [9] Chen X et al. Scientific Reports 7, 17432 (2017).
  • [10] Heap RE et al. Analyst 144(21), 6371–6381 (2019).

Content was automatically generated from an orignal PDF document using AI and may contain inaccuracies.

Downloadable PDF for viewing
 

Similar PDF

Label-free compound profiling in K562 leukemia cells by MALDI-TOF mass spectrometry using heme B as response marker
Kinase inhibition screening by label-free mass spectrometry employing the MALDI PharmaPulse HTS solution
Novel MALDI-TOF MS Workflow for Ultrahigh-Throughput Screening of Different Analytes at Each Position on a Plate
High-throughput MALDI-MS based read-out of high-density droplet microarrays facilitating next generation on-chip drug discovery